Fulcrum Therapeutics (FULC) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Downgraded | Overweight → Underweight | — | Jun 3, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $3.00 from $25.00 | Jun 2, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $4.00 from $24.00 | Jun 2, 2026 |
| Truist Securities | Downgraded | Buy → Hold | $4.00 from $17.00 | Jun 2, 2026 |
| Piper Sandler | Downgraded | Overweight → Underweight | $3.00 from $23.00 | Jun 2, 2026 |
| Stifel | Downgraded | Buy → Hold | $3.00 from $25.00 | Jun 2, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $20.00 | Jan 12, 2026 |
| Truist Securities | Maintained | Buy | $18.00 from $14.00 | Dec 11, 2025 |
| B of A Securities | Maintained | Underperform | $7.00 from $6.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $18.00 | Dec 8, 2025 |
| Piper Sandler | Maintained | Overweight | $23.00 from $16.00 | Dec 8, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $24.00 from $15.00 | Dec 8, 2025 |
| RBC Capital | Maintained | Sector Perform | $10.00 from $7.00 | Dec 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $12.00 | Nov 24, 2025 |
| Truist Securities | Initiated Coverage | Buy | $14.00 | Nov 24, 2025 |
| Piper Sandler | Maintained | Overweight | $16.00 from $12.50 | Oct 30, 2025 |
| RBC Capital | Maintained | Sector Perform | $7.00 from $5.00 | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Oct 20, 2025 |
| RBC Capital | Maintained | Sector Perform | $5.00 from $4.00 | Jul 30, 2025 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $12.00 from $4.00 | Jul 29, 2025 |
Frequently asked questions
Is FULC a buy, sell, or hold?
Analysts covering Fulcrum Therapeutics currently average a Hold rating: 0 buy, 1 hold and 1 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on FULC?
On Jun 3, 2026, JP Morgan downgraded Fulcrum Therapeutics to Underweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.